NOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent Trial Extended Follow-up

NOBORI Biolimus-Eluting versus XIENCE/PROMUS Everolimus-eluting Stent Trial Extended Follow-up - NEXT Trial: Extended Follow-up Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044050

Enrollment

2720

Registered

2021-04-27

Start date

2021-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Of the 3,235 patients enrolled in the NEXT study (1,617 BES and 1,618 EES), the patients whose 10-year follow-up data were available.

Exclusion criteria

Exclusion criteria: No specific exclusion criteria are defined.

Design outcomes

Primary

Measure	Time frame
Efficacy: Any target lesion revascularization within 10 years after percutaneous coronary intervention. Safety: The composite of cardiac death and myocardial infarction within 10 years after percutaneous coronary intervention.	—

Countries

Japan

Contacts

Public ContactHirotoshi Watanabe

Kyoto University Graduate School of Medicine Department of Cardiovascular Medicine

hwatanab@kuhp.kyoto-u.ac.jp075-751-4254

Outcome results